Publications

Article

Advancing Computational Biology and Bioinformatics Research Through Open Innovation Competitions

By: Andrea Blasco, Michael G. Endres, Rinat A. Sergeev, Anup Jonchhe, Max Macaluso, Rajiv Narayan, Ted Natoli, Jin H. Paik, Bryan Briney, Chunlei Wu, Andrew I. Su, Aravind Subramanian and Karim R. Lakhani

Open data science and algorithm development competitions offer a unique avenue for rapid discovery of better computational strategies. We highlight three examples in computational biology and bioinformatics research where the use of competitions has yielded significant... View Details

Keywords: Computational Biology; Bioinformatics; Innovation Competitions; Research; Collaborative Innovation and Invention

Read Now

December 2009
Article

Aspects of the Political Economy of Development and Synthetic Biology

By: Rachel Wellhausen and Gautam Mukunda

Keywords: Government and Politics; Economy; Growth and Development; Science

Oct 2008
Conference Presentation

The Rumpelstiltskin Effect: Synthetic Biology and International Trade

By: Gautam Mukunda and Rachel Wellhausen

15 Jun 2011 - 17 Jun 2011
Conference Presentation

A multi-disciplinary process for assessing synthetic biology applications

By: Gautam Mukunda, Allen Lin and Kenneth Oye

Keywords: Science

Keywords: by Blasco, Andrea, Michael G. Endres, Rinat A. Sergeev, Anup Jonchhe, Max Macaluso, Rajiv Narayan, Ted Natoli, Jin H. Paik, Bryan Briney, Chunlei Wu, Andrew I. Su, Aravind Subramanian, and Karim R. Lakhani; Health

21 Mar 2019
Working Paper Summaries

Advancing Computational Biology and Bioinformatics Research Through Open Innovation Competitions

Other Article

Prize-based Contests Can Provide Solutions to Computational Biology Problems

By: Karim R. Lakhani, Kevin J. Boudreau, Po-Ru Loh, Lars Backstrom, Carliss Y. Baldwin, Eric Lonstein, Mike Lydon, Alan MacCormack, Ramy A. Arnaout and Eva C. Guinan

September 15, 2021
Article

Improving Deconvolution Methods in Biology Through Open Innovation Competitions: An Application to the Connectivity Map

By: Andrea Blasco, Ted Natoli, Michael G. Endres, Rinat A. Sergeev, Steven Randazzo, Jin Hyun Paik, N.J. Maximilian Macaluso, Rajiv Narayan, Xiaodong Lu, David Peck, Karim R. Lakhani and Aravind Subramanian

A recurring problem in biomedical research is how to isolate signals of distinct populations (cell types, tissues, and genes) from composite measures obtained by a single analyte or sensor. Existing computational deconvolution approaches work well in many specific... View Details

Keywords: Deconvolution; Methods; Open Innovation Competition; Genomics; Research; Innovation and Invention

Read Now

February 2015
Article

'Open' Disclosure of Innovations, Incentives and Follow-on Reuse: Theory on Processes of Cumulative Innovation and a Field Experiment in Computational Biology

By: Kevin J. Boudreau and Karim R. Lakhani

Most of society's innovation systems―academic science, the patent system, open source, etc.―are "open" in the sense that they are designed to facilitate knowledge disclosure among innovators. An essential difference across innovation systems is whether disclosure is of... View Details

Keywords: Open Innovation; Cumulative Innovation; Incentives; Search; Disclosure And Access; Knowledge Sharing; Motivation and Incentives; Collaborative Innovation and Invention

SSRN

03 Dec 2001
Research & Ideas

Healthcare Conference Looks At Ailing Industry

Genomic Research. Even the impetus for common diseases such as diabetes and hypertension continues to elude scientists, he said. Eric S. Lander But that will change. The major achievement that underlies biology and medicine today is that... View Details

Keywords: by Martha Lagace; Health

October 2022 (Revised May 2023)
Case

Ginkgo Bioworks vs. Scorpion Capital: The Debate Over Related-Party Revenues

By: Aiyesha Dey, Jonas Heese, Suraj Srinivasan and Annelena Lobb

Ginkgo Bioworks, a synthetic biology company based in Boston, Massachusetts, faced divergent views on its revenue possibilities and accounting practices. After a report emerged accusing it of fraudulent accounting and lack of innovation, its share price plunged. But... View Details

Keywords: Fraud Allegations; Revenue; Reports; Accounting Audits; Innovation and Management; Investment; Biotechnology Industry; Boston

June 2004 (Revised May 2005)
Case

Judah Folkman and the War on Cancer

Judah Folkman, professor in the Division of Vascular Biology at Children's Hospital in Boston, is considering how best to advance the research in his lab in an era where biomedical research has gotten more interdisciplinary and collaborative. Specifically, Folkman has... View Details

Keywords: Conflict of Interests; Leadership; Research; Personal Development and Career; Health Care and Treatment; Collaborative Innovation and Invention; Biotechnology Industry; Health Industry; Boston

February 2010
Case

Amyris Biotechnologies: Commercializing Biofuel

By: Gary P. Pisano and Alison Berkley Wagonfeld

In 2009, Amyris Biotechnologies was building a plant in Brazil that used synthetic biology to convert sugarcane into both renewable fuels and renewable chemicals. The Amyris' marketing team was investigating the commercial interest for both types of products, while the... View Details

Keywords: Renewable Energy; Chemicals; Risk Management; Product Marketing; Product Development; Production; Environmental Sustainability; Commercialization; Biotechnology Industry; Brazil

October 2019 (Revised November 2019)
Case

C16 Biosciences: Lab-Grown Palm Oil

By: Jeffrey J. Bussgang and Olivia Hull

Synthetic biology start-up C16 Biosciences wants to solve a big problem: replace palm oil, a major contributor to deforestation and climate change, with a lab-grown substitute. CEO Shara Ticku has ambitious plans to supply her lab-grown palm oil to food manufacturers,... View Details

Keywords: Science-Based Business; Environmental Sustainability; Social Entrepreneurship; Product Development; Product Positioning; Venture Capital; Strategy; Decision Making; Food and Beverage Industry; Consumer Products Industry

April 2002
Case

In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen

By: Juan Enriquez-Cabot, Gary P. Pisano and Gaye Bok

Biogen is a successful biotech company facing a critical juncture. CEO John Mullen ponders how technological changes introduced into the research function will shape larger corporate decisions. This world in which biotechnology companies operated had changed... View Details

Keywords: Change; Decisions; Product Development; Research and Development; Expansion; Technology; Biotechnology Industry

November 2024
Supplement

AlphaGo (C): Birth of a New Intelligence

By: Shikhar Ghosh and Shweta Bagai

This case, the final of a three-part series, explores DeepMind's pivotal transition from mastering games to solving real-world scientific challenges. In December 2020, DeepMind's AI system AlphaFold 2 achieved a breakthrough by solving protein folding—a 50-year-old... View Details

Keywords: Autonomy; Deep Learning; Drug Discovery; Healthcare Innovation; Neural Networks; Scientific Research; Technology Startup; AI and Machine Learning; Technological Innovation; Research and Development; Business Model; Business Strategy; Open Source Distribution; Technology Industry; United States

March 2011 (Revised June 2012)
Case

Office of Technology Transfer - Shanghai Institutes for Biological Sciences

By: Willy Shih, Sen Chai, Kamen Bliznashki and Courtney Hyland

Gordon Zong is trying to teach Chinese universities and research institutes how to do effective technology transfer and IP licensing, but he is trying to do it in an environment with weak property rights and an underdeveloped support infrastructure. As the managing... View Details

Keywords: Multinational Firms and Management; Patents; Knowledge Management; Law Enforcement; Business and Government Relations; Research and Development; Biotechnology Industry; Pharmaceutical Industry; China

2001
Chapter

Publicly Funded Science and the Productivity of the Pharmaceutical Industry

By: Rebecca Henderson and Ian Cockburn

U.S. taxpayers funded $14.8 billion of health related research last year, four times the amount that was spent in 1970 in real terms. In this paper we evaluate the impact of these huge expenditures on the technological performance of the pharmaceutical industry. While... View Details

Keywords: Public Sector; Science-Based Business; Research and Development; Sovereign Finance; Pharmaceutical Industry